Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

2 clinical studies listed.

Filters:

Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma

Tundra lists 2 Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

COMPLETED

NCT03409432

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

This phase II trial studies how well brentuximab vedotin and lenalidomide work in treating patients with stage IB-IVB T-cell lymphoma that have come back or do not respond to treatment. Monoclonal antibodies, such as brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and lenalidomide may work better in treating patients with T-cell lymphoma.

Gender: All

Ages: 18 Years - Any

Updated: 2026-08-13

1 state

Lymphomatoid Papulosis
Primary Cutaneous Anaplastic Large Cell Lymphoma
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
+6
ACTIVE NOT RECRUITING

NCT02520791

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.

Gender: All

Ages: 18 Years - Any

Updated: 2026-06-26

15 states

Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type
Recurrent Grade 1 Follicular Lymphoma
+16